Overview

Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Hypothesis: Ambrisentan (Letairis ®) is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Medical University of South Carolina
Collaborator:
Gilead Sciences
Treatments:
Ambrisentan